Previous 10 |
home / stock / otskf / otskf news
Teva Pharmaceutical Industries (NYSE: TEVA ) announces positive results from two Phase 2/3 clinical trials in Japan evaluating Ajovy (fremanezumab) in patients with chronic and episodic migraine. More news on: Teva Pharmaceutical Industries Limited, Otsuka Holdings Co., Ltd., Otsuka Hold...
Otsuka Holdings ( OTCPK:OTSKF ) unit Avanir Pharmaceuticals has agreed to pay more than $108M in criminal penalties, forfeiture and civil damages over a kickback scheme aimed at boosting prescriptions for pseudobulbar affect med Nuedexta (dextromethorphan hydrobromide and quinidine sulfate...
On January 7, 2019, Axsome Therapeutics ( AXSM ) announced results from an 80-patient trial of bupropion vs AXS-05 (bupropion with dextromethorphan) in major depressive disorder ((MDD)). I recently wrote about results from the trial and the five additional upcoming catalysts for AXSM. Compar...
Otsuka Pharmaceutical Company ( OTCPK:OTSKF )( OTCPK:OTSKY ) and development partner H. Lundbeck A/S ( OTC:HLUKF )( OTCPK:HLUYY ) announce positive results from a Phase 2 clinical trial evaluating the combination of brexpiprazole and Pfizer's ( PFE +0.7% ) Zoloft (sertraline HCl) for t...
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Otsuka failure portends termination of an important AML study Company: Otsuka ( OTCPK:O...
The following slide deck was published by Otsuka Holdings Co. Ltd. ADR in conjunction with their 2018 Q1 earnings Read more ...
The FDA approves Otsuka Pharmaceutical's ( OTCPK:OTSKF )( OTCPK:OTSKY ) JYNARQUE (tolvaptan) to slow the decline in kidney function in patients with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), an inherited disorder characterized by the formation of cysts i...